Articles tagged "Kidney transplantation"

2021 American Transplant Congress
Combined Impact of Pre-sensitization and Delayed Graft Function on Allograft Rejection in Deceased Donor Kidney Transplantation: A Nationwide Cohort Study
H. Lee¹, Y. Park¹, T. Ban², S. Song³, S. Song⁴, J. Yang⁵, C. Ahn⁵, C. Yang¹, B. Chung¹
¹Division of Nephrology, Department of Internal Medicine, Seoul St. Mary’s hospital, Seoul, Korea, Republic of, ²Division of Nephrology, Department of Internal Medicine, Eunpyeong St. Mary’s hospital, Seoul, Korea, Republic of, ³Organ Transplantation Center and Department of Internal Medicine, Pusan National University Hospital, Pusan, Korea, Republic of, ⁴Department of Surgery, Ewha Womans University Medical Center, Seoul, Korea, Republic of, ⁵Department of Nephrology, Seoul National University Hospital, Seoul, Korea, Republic of
*Purpose: The aim of this study is to investigate whether or not delayed graft function (DGF) and pre-transplant sensitization has a synergistic adverse effect on…
2021 American Transplant Congress
Donor-Derived Cell-Free DNA as a Surrogate Marker for “Allograft Quiescence” After Kidney Transplantation
J. S. Bromberg¹, L. Bu², G. Gupta³, I. Moinuddin³, S. Anand⁴, A. Pai⁵, T. Alhamad⁶, V. Bowers⁷, S. Ghosh⁸, W. Tian⁸, E. Stites⁹
¹University of Maryland School of Medicine, Baltimore, MD, ²University of Minnesota, Minneapolis, MN, ³Virginia Commonwealth University, Richmond, VA, ⁴Intermountain Medical Center, Murray, UT, ⁵University of Texas McGovern Medical School, Houston, TX, ⁶Washington University in St. Louis, St. Louis, MO, ⁷Tampa General Hospital, Tampa, FL, ⁸CareDx, Brisbane, CA, ⁹University of Colorado, Aurora, CO
*Purpose: Donor-derived cell-free DNA (dd-cfDNA; AlloSure®) and the association with active rejection (AR) was described by Bloom et al, however subsequent insights have suggested this…
2021 American Transplant Congress
Donor CPR and Solid Organ Transplantation
E. Larsen¹, K. Cardoza², K. Robichaux³, A. Kumar¹, V. Bowers⁴, J. Buggs⁴
¹Morsani College of Medicine, University of South Florida, Tampa, FL, ²Honors College, University of Tampa, Tampa, FL, ³Honors College, University of South Florida, Tampa, FL, ⁴Transplant Surgery, Tampa General Hospital, Tampa, FL
*Purpose: In 2010, the American Heart Association and Emergency Cardiac Care (AHA ECC) set a 10-year impact goal of doubling cardiac arrest survival by 2020.…
2021 American Transplant Congress
Machine Learning Approaches for Post-transplant Kidney Outcome Prediction
H. Ghali¹, D. Won¹, S. Yoon¹, A. Friedman²
¹Systems Science and Industrial Engineering, SUNY Binghamton, Binghamton, NY, ²LiveOnNY, New York, NY
*Purpose: Determine a robust prediction model for kidney graft survival based on analyzing a combination of decisive factors such as donor and recipient characteristics, biopsy,…
2021 American Transplant Congress
Influence of Vitamin D Status on the Prognosis of Covid 19 in Patients with Kidney Transplant
J. Ugalde-Altamirano, I. Revuelta, A. Carrillo, M. Xipell, F. Cofan, N. Esforzado, E. Montagud, G. Piñeiro, A. Molina, P. Ventura, D. Cucchiari, F. Oppenheimer, F. Diekmann, J. Campistol, B. Bayes, J. Torregrosa
Nephrology, Hospital Clinic de Barcelona, Barcelona, Spain
*Purpose: The protective role of Vitamin D as an immunomodulator has been demonstrated in different pathologies included the viral etiology. This effect has been described…
2020 American Transplant Congress
How Prepared are Potential Donors to Donate?: Racial/Ethnic Differences in Potential Kidney Donors’ Knowledge and Education Before Starting Evaluation
A. Waterman¹, O. N. Ranasinghe¹, Y. Cui², J. L. Beaumont², D. Adey³, U. Reddy⁴, B. Campbell⁵, F. L. Weng⁶
¹Division of Nephrology, David Geffen School of Medicine, Los Angeles, CA, ²Terasaki Research Institute, Los Angeles, CA, ³Division of Nephrology, UCSF Health, San Francisco, CA, ⁴UC Irvine, Irvine, CA, ⁵Cedars Sinai Medical Center, Los Angeles, CA, ⁶St. Barnabas Medical Center, Livingston, NJ
*Purpose: Potential living donors of different races/ethnicities present for kidney donor evaluation with varying levels of knowledge.*Methods: We surveyed potential living donors about how they…
2020 American Transplant Congress
Socioeconomic and Financial Challenges Affecting 2500 Potential Living Kidney Donors’ Pursuit of Donation
A. Waterman¹, O. N. Ranasinghe¹, Y. Cui², J. L. Beaumont², D. Adey³, U. Reddy⁴, B. Campbell⁵, F. L. Weng⁶
¹Division of Nephrology, David Geffen School of Medicine, Los Angeles, CA, ²Terasaki Research Institute, Los Angeles, CA, ³UCSF Health, San Francisco, CA, ⁴UC Irvine, Irvine, CA, ⁵Cedars Sinai Medical Center, Los Angeles, CA, ⁶St. Barnabas Medical Center, Livingston, CA
*Purpose: To identify financial factors that affect living kidney donors’ attitudes and progress towards donation, we conducted a survey of 2576 potential living donors [48%…
2020 American Transplant Congress
Contralateral Upper Tracturothelial Carcinoma after Primary Radical Nephroureterectomy in Kidney Transplant Patients
Z. Wang, J. Lin, Y. Zhu, Y. Guo, Y. Tian
Capital Medical University, Beijing, China
*Purpose: The purpose of the present study was to evaluate the incidence and risk factors of contralateral upper tract urothelial carcinoma (UTUC) after primary radical…
2020 American Transplant Congress
Improving Access to Transplantation and Outcomes for African American Patients
D. Bekbolsynov, O. Ekwenna, B. Mierzejewska, J. Borucka, S. A. Khuder, M. Rees, R. Green, S. Stepkowski
University of Toledo, Toledo, OH
*Purpose: Black or African American patients are clearly disadvantaged in comparison to Caucasian patients both in terms of the access to kidney transplantation and post-transplant…
2020 American Transplant Congress
In Silico Deconvolution of Whole Blood RNA-Seq Data from Iscalimab Phase IIa Study in Renal Transplant Reveals Insights Into Mechanism of Action and Superiority of Iscalimab Compared to Tacrolimus
J. S. Rush
Autoimmunity, Transplantation and Inflammation, Novartis Institutes for Biomedical Research, Basel, Switzerland
*Purpose: A recent Phase 2 clinical study indicated that iscalimab, a pathway blocking, non-depleting anti-CD40 antibody, showed non-inferiority on a composite clinical endpoint, and improved…